Answers are grounded in this paper and cite their sources.
Alternative splicing diversifies the transcriptome and shapes cell fate across development, tissue function, and disease. Single-cell RNA sequencing can link isoforms to cell states, but these methods often lack the throughput and coverage to accurately call splice variants. As a result, rare isoforms are often missed, especially in underrepresented cell types. Here, we present Catch*ReSeq, a targeted enrichment method that yields isoform-resolved readouts linked to host transcriptomes from standard single-cell libraries for the capture of rare isoforms. We found more oligo(dT)-primer cDNA originating from internal A-rich sequences than from terminal polyA tails (80-fold enrichment for simian immunodeficiency virus (SIV) and over 6-fold for host transcripts), fracturing cDNA and obscuring isoforms. Catch*ReSeq exploits this fracture to infer each molecule's isoform of origin. In SIV-infected macaque CD4+ T cells, Catch*ReSeq detected up to 13 times as many infected cells as standard 10X and resolved spliced viral isoforms that 10X missed entirely. Splice+ cells carried a translational host program independent of how much virus they transcribed, a distinction invisible to standard single-cell sequencing methods. From macaque and PWH on ART, Catch*ReSeq recovered 13-fold more virus-transcribing cells than 10X, including splice+ cells. We also demonstrated the generalizability of Catch*ReSeq across biological systems by applying it in combination with lineage barcoding to probe alternative splicing in clonally expanded CD4+ T cells, and separately in mouse liver regeneration. As Catch*ReSeq works with archived cDNA and can be redesigned for new targets after the fact, it allows rare isoform profiling on existing biobanked and clinical samples.
No takes yet. Share an insight, caveat, or question.
Grody et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: